Evidence map›Paper›PMID 28924103›Full record

Trial reportJournal of atherosclerosis and thrombosis2018

Pravastatin Reduces the Risk of Atherothrombotic Stroke when Administered within Six Months of an Initial Stroke Event.

Naohisa Hosomi, Yoji Nagai, Kazuo Kitagawa, Yoko Nakagawa, Shiro Aoki, Tomohisa Nezu, Tatsuo Kagimura, Hirofumi Maruyama, Hideki Origasa, Kazuo Minematsu and 3 more

Registry-linked trialOpen access · diamondAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of atherosclerosis and thrombosis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00221104 (Secondary Prevention With HMG-CoA Reductase Inhibitor Against Stroke), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00221104 phase3completednot on this map

Secondary Prevention With HMG-CoA Reductase Inhibitor Against Stroke

TypeinterventionalSponsorTranslational Research Center for Medical Innovation, Kobe, Hyogo, JapanRan2004Enrolled1,578ConditionsIschemic StrokeArmsPravastatin
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 2 countries.

Naohisa HosomiDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences.
Yoji NagaiCenter for Clinical Research, Kobe University Hospital.
Kazuo KitagawaDepartment of Neurology, Tokyo Women's Medical University School of Medicine.
Yoko NakagawaDivision of Medical Statistics, Translational Research Informatics Center, Foundation for Biomedical Research and Innovation.
Shiro AokiDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences.
Tomohisa NezuDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences.
Tatsuo KagimuraDivision of Medical Statistics, Translational Research Informatics Center, Foundation for Biomedical Research and Innovation.
Hirofumi MaruyamaDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences.
Hideki OrigasaDivision of Biostatistics and Clinical Epidemiology, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences.
Kazuo MinematsuNational Cerebral and Cardiovascular Center.
Shinichiro UchiyamaInternational University of Health and Welfare, Center for Brain and Cerebral Vessels, Sanno Hospital and Sanno Medical Center.
Masayasu MatsumotoDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences.
J-STARS collaborators
Hiroshima University · JPFoundation for Biomedical Research and Innovation · JPInternational University of Health and Welfare · JPKobe University Hospital · JPNational Cerebral and Cardiovascular Center · JPTokyo Women's Medical University · JPTranslational Research Informatics Center (Japan) · JPUniversity of Toyama · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe J-STARS study examined whether pravastatin (10 mg/day) reduces recurrence of stroke in non-cardioembolic ischemic stroke patients who were enrolled within 1 month to 3 years after initial stroke events (ClinicalTrials.gov, NCT00221104). The main results showed that the frequency of atherothrombotic stroke was low in pravastatin-treated patients, although no effect of pravastatin was found for the other stroke subtypes. We evaluated differences of early (within 6 months) or late (after 6 months) pravastatin treatment benefits on the incidence of stroke or transient ischemic attack (TIA), as well as atherothrombotic stroke and the other subtypes.

methodsSubjects in the J-STARS study were classified into two cohorts, depending on whether they enrolled early (1 to 6 months) or late (6 months to 3 years) following initial stroke events.

resultsA total of 1578 patients (491 female, 66.2±8.5 years) were randomly assigned to either the pravastatin group (n=793; n=426 in the early cohort, n=367 in the late cohort) or the control group (n=785; n=417 in the early cohort, n=368 in the late cohort). During the follow-up of 4.9± 1.4 years, the rate of atherothrombotic stroke was lower in the pravastatin group compared to controls in the early cohort (0.24 vs. 0.88%/year, p=0.01) but not in the late cohort (0.17 vs. 0.39%/year, p=0.29). However, this difference of pravastatin effect on atherothrombotic stroke was not significantly interacted by the early or late cohort (p=0.59). The incidence rates of other stroke subtype were not different in between pravastatin and control groups despite the timing of entry.

conclusionsPravastatin is likely to reduce atherothrombotic stroke in patients enrolled within 6 months after stroke onset. However, the clinical efficacy for prevention of recurrent stroke was not conclusive with earlier statin treatment.

Indexed as

AgedAged, 80 and overCohort StudiesDrug Administration ScheduleFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIncidenceJapanMaleMiddle AgedPravastatinProportional Hazards ModelsRecurrenceRiskStrokeHydroxymethylglutaryl-CoA Reductase InhibitorsPravastatinAtherothromboticCholesterolPreventionStatinStroke

Identifiers

PMID28924103
PMCPMC5868512
OpenAlexW2756170709

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.